Pipeline

Robust Pipeline of Precision Therapeutics

At Atavistik Bio, we are developing a pipeline of allosteric therapeutics against validated targets to address patient populations with significant unmet needs. Our AMPS^TM platform has enabled us to efficiently deliver differentiated small molecule allosteric inhibitors for clinically validated targets that achieve superior efficacy and tolerability profiles to improve patient outcomes.

Program/Target

Indication

Discovery

Lead Optimization

IND Enabling

Clinical STAGE

ATV-1601

AKT1

HHT and Vascular Malformations

Stage - Clinical

Hereditary Hemorrhagic Telangiectasia (HHT) is a severe bleeding disorder that affects more than 1.6 million people globally, with no approved therapies currently available. AKT1 hyperactivation is a hallmark of HHT and has been shown to drive the vascular pathology of HHT.

Selectively inhibiting AKT1, the primary AKT isoform and driver of abnormal endothelial growth implicated in HHT, offers a novel and potentially disease-modifying therapeutic approach for this difficult disease. Although there has been substantial investment in pan-AKT inhibitors, their use is limited by AKT2-driven toxicities, most notably hyperglycemia, which impact tolerability and restrict their use for chronic dosing. Atavistik Bio has developed an oral allosteric inhibitor that selectively inhibits AKT1, overcoming the shortcomings of pan-AKT inhibitors and offering improved therapeutic potential and tolerability.

Atavistik has developed an oral allosteric inhibitor that selectively inhibits AKT1, overcoming the shortcomings of pan-AKT inhibitors and offering improved therapeutic potential and tolerability. Anticipate initiating clinical trial in HHT early 2026.

Program 2

JAK2^V617F

Myeloproliferative neoplasms

Stage - Lead Optimization

JAK2^V617F is the most common driver mutation in myeloproliferative neoplasms (MPNs), affecting ~95% of polycythemia vera (PV), 60% of essential thrombocythemia (ET) and 55% of myelofibrosis (MF) patients. Selectively targeting JAK2^V617F has the potential to reduce mutant allele burden, preserve normal bone marrow function, and have a disease modifying impact that will substantially improve long term outcomes for patients with MPNs.

Approved pan-JAK inhibitors, such as ruxolitinib, provide symptom relief, but non-selectively inhibit both mutant and wild-type JAK2. This limits their ability to reduce JAK2^V617F mutant allele burden and can disrupt normal blood cell production regulated by wild-type JAK2, contributing to adverse events and treatment discontinuation.

Atavistik has discovered novel allosteric JAK2^V617F selective inhibitors that suppress mutant-dependent signaling while sparing wild-type JAK2. Compounds with favorable PK properties and tolerability are being advanced for further development. These candidates have the potential to address the significant unmet needs of patients with MPNs by providing disease-modifying efficacy while avoiding off-target hematological effects associated with wild-type JAK inhibition.

Metabolic Disease

Program 4

Undisclosed

Hepatic Encephalopathy

Stage - Lead Optimization

Partnerships

Partner:

Undisclosed

Oncology

Stage - Discovery